Serum osteocalcin is associated with subjective stress in people with depression and type 2 diabetes.

Oct 12, 2020

Contributor: Michelle M Nguyen,Natasha Z Anita,Lina Darwish,Chelsi Major-Orfao,Jessica Colby-Milley,Sophie K Wong,Kim S Sugamori,Krista L Lanctôt,Nathan Herrmann,Paul I Oh,Pearl Yang,Baiju R Shah,Jeremy Gilbert,Angela Assal,Ilana J Halperin,Jane Mitchell,Walter Swardfager

Low serum osteocalcin is a risk factor for type 2 diabetes mellitus (T2DM), and osteocalcin release from bone is associated with an acute stress response in mice. Both diabetes and stress are associated with depression. Here, we assess relationships between serum osteocalcin, depression and subjective stress in people with T2DM.
Participants with T2DM (HbA1c above 6.4 %, impaired fasting glucose or impaired glucose tolerance) were assessed for a major depressive episode using the research version of the Structured Clinical Interview for DSM-5 depression criteria (SCID-5RV). Subjective stress over the past month was assessed using the Perceived Stress Scale (PSS). Serum carboxylated (cOCN) and fully decarboxylated (dcOCN) osteocalcin were assayed from fasting morning blood by commercial enzyme-linked immunosorbent assay.
Among 95 participants (mean age 62.4 ± 9.9, 51 % women), 22 % were experiencing a depressive episode (9 men, 12 women). The presence of a depressive episode was not associated with dcOCN or cOCN concentrations; however, higher concentrations of cOCN were associated with higher PSS scores in participants with depression (r = 0.585, p = 0.005). In an analysis of covariance model controlling for age, sex, body mass index, glycemic control (glycosylated hemoglobin), insulin resistance (homeostatic model), depression, and antidepressant use, cOCN was associated with PSS scores (F=10.302, p = 0.002), and this relationship was stronger in those with depression (depression × cOCN interaction F=4.978, p = 0.028). Although associations between dcOCN concentrations and PSS scores did not reach significance, the same trend seen with cOCN concentrations was observed in participants with depression for dcOCN (r=0.365, p=0.10), and for a depression × dcOCN interaction associated with PSS scores in the whole group (F=2.165, p = 0.15).
Osteocalcin is a neuroendocrine marker associated with perceived chronic stress among people with T2DM experiencing a depressive episode.

Copyright © 2020 Elsevier Ltd. All rights reserved.

Author

admin

View all posts

About The Expert

Michelle M Nguyen

Department of Pharmacology & Toxicology, University of Toronto, Medical Sciences Building, 1 King’s College Circle Room 4207, Toronto, Ontario, M5S 1A8, Canada; Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada; Cardiovascular Prevention and Rehabilitation Program, University Health Network Toronto Rehabilitation Institute, 347 Rumsey Rd, East York, Ontario, M4G 2V6, Canada.

Natasha Z Anita

Department of Pharmacology & Toxicology, University of Toronto, Medical Sciences Building, 1 King’s College Circle Room 4207, Toronto, Ontario, M5S 1A8, Canada; Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada; Cardiovascular Prevention and Rehabilitation Program, University Health Network Toronto Rehabilitation Institute, 347 Rumsey Rd, East York, Ontario, M4G 2V6, Canada.

Lina Darwish

Department of Pharmacology & Toxicology, University of Toronto, Medical Sciences Building, 1 King’s College Circle Room 4207, Toronto, Ontario, M5S 1A8, Canada; Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada; Cardiovascular Prevention and Rehabilitation Program, University Health Network Toronto Rehabilitation Institute, 347 Rumsey Rd, East York, Ontario, M4G 2V6, Canada.

Chelsi Major-Orfao

Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada; Cardiovascular Prevention and Rehabilitation Program, University Health Network Toronto Rehabilitation Institute, 347 Rumsey Rd, East York, Ontario, M4G 2V6, Canada.

Jessica Colby-Milley

Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada; Cardiovascular Prevention and Rehabilitation Program, University Health Network Toronto Rehabilitation Institute, 347 Rumsey Rd, East York, Ontario, M4G 2V6, Canada.

Sophie K Wong

Department of Pharmacology & Toxicology, University of Toronto, Medical Sciences Building, 1 King’s College Circle Room 4207, Toronto, Ontario, M5S 1A8, Canada; Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada; Cardiovascular Prevention and Rehabilitation Program, University Health Network Toronto Rehabilitation Institute, 347 Rumsey Rd, East York, Ontario, M4G 2V6, Canada.

Kim S Sugamori

Department of Pharmacology & Toxicology, University of Toronto, Medical Sciences Building, 1 King’s College Circle Room 4207, Toronto, Ontario, M5S 1A8, Canada.

Krista L Lanctôt

Department of Pharmacology & Toxicology, University of Toronto, Medical Sciences Building, 1 King’s College Circle Room 4207, Toronto, Ontario, M5S 1A8, Canada; Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada; Cardiovascular Prevention and Rehabilitation Program, University Health Network Toronto Rehabilitation Institute, 347 Rumsey Rd, East York, Ontario, M4G 2V6, Canada; Department of Psychiatry University of Toronto, 250 College Street 8th floor, Toronto, Ontario, M5T 1R8, Canada.

Nathan Herrmann

Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada; Department of Psychiatry University of Toronto, 250 College Street 8th floor, Toronto, Ontario, M5T 1R8, Canada; Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.

Paul I Oh

Cardiovascular Prevention and Rehabilitation Program, University Health Network Toronto Rehabilitation Institute, 347 Rumsey Rd, East York, Ontario, M4G 2V6, Canada.

Pearl Yang

Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.

Baiju R Shah

Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada; Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.

Jeremy Gilbert

Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.

Angela Assal

Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.

Ilana J Halperin

Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.

Jane Mitchell

Department of Pharmacology & Toxicology, University of Toronto, Medical Sciences Building, 1 King’s College Circle Room 4207, Toronto, Ontario, M5S 1A8, Canada.

Walter Swardfager

Department of Pharmacology & Toxicology, University of Toronto, Medical Sciences Building, 1 King’s College Circle Room 4207, Toronto, Ontario, M5S 1A8, Canada; Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada; Cardiovascular Prevention and Rehabilitation Program, University Health Network Toronto Rehabilitation Institute, 347 Rumsey Rd, East York, Ontario, M4G 2V6, Canada; Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada. Electronic address: w.swardfager@utoronto.ca.

References

PubMed